Post-Transplant Cyclophosphamide Improves Outcomes of ALL Patients Receiving Allogeneic Hematopoietic Cell Transplantation (HSCT) Compared to Standard GVHD Prophylaxis

Key Points

• Improved outcomes are observed with cyclophosphamide in preventing graft-versus-host disease.
• The study shows a significant enhancement when compared to standard prophylaxis techniques for ALL patients.
• Assessment compares the clinical effectiveness of cyclophosphamide versus traditional GVHD prevention methods.
• Results suggest this approach could change standard treatment practices for ALL in transplant settings.